Correlates of improved outcomes in patients with COVID-19 treated in US emergency departments

IF 2.7 3区 医学 Q1 EMERGENCY MEDICINE
Wendy S. Slutske PhD , Julie M. Kirsch PhD , Thomas M. Piasecki PhD , Karen L. Conner MPH , Brian Williams MD , Michael C. Fiore MD, MPH, MBA , Steven L. Bernstein MD
{"title":"Correlates of improved outcomes in patients with COVID-19 treated in US emergency departments","authors":"Wendy S. Slutske PhD ,&nbsp;Julie M. Kirsch PhD ,&nbsp;Thomas M. Piasecki PhD ,&nbsp;Karen L. Conner MPH ,&nbsp;Brian Williams MD ,&nbsp;Michael C. Fiore MD, MPH, MBA ,&nbsp;Steven L. Bernstein MD","doi":"10.1016/j.ajem.2024.09.035","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The COVID-19 pandemic was managed in part by the rapid development of vaccines, diagnostics, and therapeutics including antiviral agents and advances in emergency airway and ventilatory management. The impact of these therapeutic advances on clinically pertinent metrics of emergency care have not been well-studied.</p></div><div><h3>Methods</h3><p>We abstracted data from emergency department (ED) visits made to 21 US health systems during the first two years of the pandemic, from February 1, 2020 to January 31, 2022. These health systems were participants in the NIH-supported COVID EHR Cohort, in which the University of Wisconsin served as the coordinating site. Limited patient-level data files were submitted monthly. Data elements included demographic and clinical variables, as well as standard measures of ED outcomes including 72-h returns, 72-h returns leading to readmission, and in-hospital mortality. Multivariable models were fitted to identify correlates of each of the dependent variables. A test for trend was used to detect changes in outcomes over time.</p></div><div><h3>Results</h3><p>During the two-year period, 150,357 individuals aged 18 years or older visited the ED. The median age was 45.4 years (IQR 27), 58.1 % were female, 49 % were White, 18.3 % Hispanic/Latino, and 45 % were publicly insured or uninsured. The prevalence of 72-h ED returns, readmissions, and in-hospital mortality significantly declined across the two-year period. SARS-CoV-2 vaccination was associated with reduced ED returns and mortality. Therapeutic agents were associated with increased mortality risk but were likely confounded by unmeasured covariates.</p></div><div><h3>Conclusions</h3><p>Operational and clinical outcomes of ED-based treatment of individuals with COVID-19 improved in the first two years of the pandemic. This improvement is likely multifactorial and includes the development and deployment of SARS-CoV-2-specific vaccines, therapeutic agents, and improved healthcare delivery in the ED and elsewhere addressing management of airway and ventilatory status, as well as increased innate immunity in the general population.</p></div>","PeriodicalId":55536,"journal":{"name":"American Journal of Emergency Medicine","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Emergency Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0735675724004765","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"EMERGENCY MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The COVID-19 pandemic was managed in part by the rapid development of vaccines, diagnostics, and therapeutics including antiviral agents and advances in emergency airway and ventilatory management. The impact of these therapeutic advances on clinically pertinent metrics of emergency care have not been well-studied.

Methods

We abstracted data from emergency department (ED) visits made to 21 US health systems during the first two years of the pandemic, from February 1, 2020 to January 31, 2022. These health systems were participants in the NIH-supported COVID EHR Cohort, in which the University of Wisconsin served as the coordinating site. Limited patient-level data files were submitted monthly. Data elements included demographic and clinical variables, as well as standard measures of ED outcomes including 72-h returns, 72-h returns leading to readmission, and in-hospital mortality. Multivariable models were fitted to identify correlates of each of the dependent variables. A test for trend was used to detect changes in outcomes over time.

Results

During the two-year period, 150,357 individuals aged 18 years or older visited the ED. The median age was 45.4 years (IQR 27), 58.1 % were female, 49 % were White, 18.3 % Hispanic/Latino, and 45 % were publicly insured or uninsured. The prevalence of 72-h ED returns, readmissions, and in-hospital mortality significantly declined across the two-year period. SARS-CoV-2 vaccination was associated with reduced ED returns and mortality. Therapeutic agents were associated with increased mortality risk but were likely confounded by unmeasured covariates.

Conclusions

Operational and clinical outcomes of ED-based treatment of individuals with COVID-19 improved in the first two years of the pandemic. This improvement is likely multifactorial and includes the development and deployment of SARS-CoV-2-specific vaccines, therapeutic agents, and improved healthcare delivery in the ED and elsewhere addressing management of airway and ventilatory status, as well as increased innate immunity in the general population.

在美国急诊科接受治疗的 COVID-19 患者疗效改善的相关因素
背景COVID-19 大流行的部分原因是疫苗、诊断和治疗(包括抗病毒药物)的快速发展以及气道和呼吸道急救管理的进步。我们从大流行头两年(2020 年 2 月 1 日至 2022 年 1 月 31 日)期间 21 个美国医疗系统的急诊科(ED)就诊数据中提取了摘要。这些医疗系统都是美国国立卫生研究院(NIH)支持的 COVID EHR 群体的参与者,威斯康星大学是该群体的协调机构。每月提交有限的患者级数据文件。数据元素包括人口统计学和临床变量,以及 ED 结果的标准测量值,包括 72 小时返院率、72 小时返院导致再入院率和院内死亡率。多变量模型用于确定每个因变量的相关因素。结果在两年时间内,150357 名 18 岁或以上的人到急诊室就诊。中位年龄为 45.4 岁(IQR 为 27),58.1% 为女性,49% 为白人,18.3% 为西班牙/拉丁美洲人,45% 有公共保险或无保险。72 小时内急诊室复诊率、再入院率和院内死亡率在两年期间显著下降。接种 SARS-CoV-2 疫苗与减少急诊室复诊率和死亡率有关。治疗药物与死亡率风险增加有关,但可能与未测量的协变量有关。这种改善可能是多因素的,包括 SARS-CoV-2 特异性疫苗、治疗药物的开发和应用,急诊室和其他地方医疗服务的改善,气道和通气状态的管理,以及普通人群先天免疫力的提高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.00
自引率
5.60%
发文量
730
审稿时长
42 days
期刊介绍: A distinctive blend of practicality and scholarliness makes the American Journal of Emergency Medicine a key source for information on emergency medical care. Covering all activities concerned with emergency medicine, it is the journal to turn to for information to help increase the ability to understand, recognize and treat emergency conditions. Issues contain clinical articles, case reports, review articles, editorials, international notes, book reviews and more.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信